Physician profile
Allison Bunnell
NPI 1861800013
$1,539.22
in general payments reported to CMS, 2019-2025
23 companies · $515 in 2025
The $515 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $238 · 2023: $266 · 2024: $335 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $238.28 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $144.47 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $143.58 | 2023-2025 | Invega Sustenna |
| Abbvie INC. | $137.92 | 2021-2025 | |
| Exact Sciences Corporation | $122.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $116.70 | 2022-2025 | |
| Novo Nordisk INC | $92.72 | 2021-2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.81 | 2024-2025 | Caplyta |
| Dexcom, INC. | $69.69 | 2022 | |
| Lilly USA, LLC | $65.82 | 2022-2025 | Mounjaro, Zepbound |
| Organon LLC | $57.30 | 2021-2023 | Nexplanon |
| Alkermes, INC. | $45.55 | 2022-2023 | Vivitrol |
| Indivior INC. | $39.01 | 2021-2024 | Sublocade |
| Vanda Pharmaceuticals INC. | $36.02 | 2022-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $20.19 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.95 | 2025 | Evenity |
| Astellas Pharma US INC | $18.30 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $16.73 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $15.08 | 2025 | Vaxneuvance, Enflonsia, M-M-R II |
| Axsome Therapeutics, INC. | $14.73 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $14.50 | 2025 | Voquezna |
| Hollister Incorporated | $13.91 | 2023 | New Image, Adapt Ceraring |
| Shield Therapeutics INC | $13.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Bunnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.